Capricor Therapeutics Stock Debt To Equity
| CAPR Stock | USD 19.04 0.02 0.10% |
Capricor Therapeutics fundamentals help investors to digest information that contributes to Capricor Therapeutics' financial success or failures. It also enables traders to predict the movement of Capricor Stock. The fundamental analysis module provides a way to measure Capricor Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Capricor Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.01 | 0.01 |
Capricor | Debt To Equity |
Capricor Therapeutics Company Debt To Equity Analysis
Capricor Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Capricor Therapeutics Debt To Equity | 0.15 % |
Most of Capricor Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Capricor Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Capricor Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Capricor Therapeutics is extremely important. It helps to project a fair market value of Capricor Stock properly, considering its historical fundamentals such as Debt To Equity. Since Capricor Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Capricor Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Capricor Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Capricor Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Capricor Therapeutics has a Debt To Equity of 0.146%. This is 99.73% lower than that of the Biotechnology sector and 99.25% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.7% higher than that of the company.
Capricor Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Capricor Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Capricor Therapeutics could also be used in its relative valuation, which is a method of valuing Capricor Therapeutics by comparing valuation metrics of similar companies.Capricor Therapeutics is currently under evaluation in debt to equity category among its peers.
Capricor Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Capricor Therapeutics from analyzing Capricor Therapeutics' financial statements. These drivers represent accounts that assess Capricor Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Capricor Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 4.8M | 53.4M | 67.7M | 94.8M | 130.9M | 137.5M | |
| Enterprise Value | 4.2M | 21.1M | 35.6M | 87.7M | 118.5M | 124.4M |
Capricor Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Capricor Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Capricor Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Capricor Fundamentals
| Return On Equity | -3.93 | ||||
| Return On Asset | -0.44 | ||||
| Profit Margin | (1.47) % | ||||
| Operating Margin | (5.75) % | ||||
| Current Valuation | 772.36 M | ||||
| Shares Outstanding | 45.47 M | ||||
| Shares Owned By Insiders | 16.72 % | ||||
| Shares Owned By Institutions | 18.51 % | ||||
| Number Of Shares Shorted | 5.28 M | ||||
| Price To Earning | 42.39 X | ||||
| Price To Book | 12.54 X | ||||
| Price To Sales | 37.31 X | ||||
| Revenue | 25.18 M | ||||
| Gross Profit | 1.75 M | ||||
| EBITDA | (23.01 M) | ||||
| Net Income | (22.29 M) | ||||
| Cash And Equivalents | 51.42 M | ||||
| Cash Per Share | 2.11 X | ||||
| Total Debt | 2.24 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 2.69 X | ||||
| Book Value Per Share | 0.73 X | ||||
| Cash Flow From Operations | (25.6 M) | ||||
| Short Ratio | 2.33 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Target Price | 41.29 | ||||
| Number Of Employees | 101 | ||||
| Beta | 4.02 | ||||
| Market Capitalization | 866.66 M | ||||
| Total Asset | 58.73 M | ||||
| Retained Earnings | (159.37 M) | ||||
| Working Capital | 19.59 M | ||||
| Current Asset | 22.4 M | ||||
| Current Liabilities | 6.67 M | ||||
| Net Asset | 58.73 M |
About Capricor Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Capricor Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Capricor Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Capricor Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Capricor Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Capricor Stock
Moving against Capricor Stock
| 0.94 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.86 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.82 | RGNX | Regenxbio | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.74 | INKT | Mink Therapeutics | PairCorr |
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.